Linked Life Data

17594928

Source:http://linkedlifedata.com/resource/pubmed/id/17594928

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-6-27
pubmed:abstractText
Mantle cell lymphoma (MCL) accounts for 3-10% of all non-Hodgkin's lymphomas, with median overall survival not exceeding 3-4 years. Rituximab in combination with the Hyper-CVAD regimen appears the most promising regimen; thus, we adopted it as a first-line treatment strategy in a series of 24 patients. In addition to evaluation of clinical success of the regimen, we investigated a possible role of polymorphism in IgG Fc receptors, FCgammaRIIIa and FCgammaRIIa. The frequencies of FCgammaRIIIa-158 were as follows: V/V=4/24 (17%); V/F=16/24 (66%); F/F=4/24 (17%). Those of the FCgammaRIIa-131 polymorphism were H/H=11/24 (46%), H/R=9/24 (37%), R/R=4/24 (17%). The overall response rate was 62.5%, with 33% of complete responses (CRs) after four cycles of R-Hyper-CVAD. Two-year progression-free survival (PFS) was 78% for 158V/V patients vs 75% for cases carrying phenylalanine (p=0.88). When the FCgammaRIIa polymorphism was assessed, the 2-year PFS was 82% for 131H/H patients vs 75% for those carrying arginine (p=0.26). Eighty-three percent of cases achieved Polymerase Chain Reaction (PCR)-negativity: the progression rate was significantly influenced by the minimal residual disease clearance, with 12% progression in the subgroup of PCR-negative cases versus 67% progression in PCR-positive cases (p=0.008). The achievement of PCRnegativity was not significantly influenced by FCgammaR polymorphisms. Results confirm that rituximab plus Hyper-CVAD is an effective regimen for the induction of prolonged remission in patients with aggressive MCL and suggest that rituximab efficacy is independent of the FCgammaR polymorphisms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1120-009X
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
315-21
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17594928-Adult, pubmed-meshheading:17594928-Aged, pubmed-meshheading:17594928-Antibodies, Monoclonal, pubmed-meshheading:17594928-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:17594928-Antigens, CD, pubmed-meshheading:17594928-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17594928-Cyclophosphamide, pubmed-meshheading:17594928-Dexamethasone, pubmed-meshheading:17594928-Disease-Free Survival, pubmed-meshheading:17594928-Doxorubicin, pubmed-meshheading:17594928-Female, pubmed-meshheading:17594928-Humans, pubmed-meshheading:17594928-Lymphoma, Mantle-Cell, pubmed-meshheading:17594928-Male, pubmed-meshheading:17594928-Middle Aged, pubmed-meshheading:17594928-Polymerase Chain Reaction, pubmed-meshheading:17594928-Polymorphism, Genetic, pubmed-meshheading:17594928-Prospective Studies, pubmed-meshheading:17594928-Receptors, IgG, pubmed-meshheading:17594928-Vincristine
pubmed:year
2007
pubmed:articleTitle
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
pubmed:affiliation
Department of Oncology, Section of Hematology, University of Pisa, Pisa, Italy. s.galimberti@med.unipi.it
pubmed:publicationType
Journal Article, Clinical Trial